Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


E-Submission Part Of FDA Reg Reform Plan; Alzheimer’s Data Standard About To Debut

Executive Summary

Standards for organizing clinical data from research in some major diseases are taking shape as FDA moves to clear a regulatory path that eventually could allow all submissions to be done electronically.

Related Content

Sponsors Might Share Research Committees As Pressure Mounts To Share Data
Chelsea Vows To Resolve Latest Regulatory Woes With Northera Quickly
Track-and-Trace Bill Clears House With New Electronic Labeling Language
FDA Clinical Data Standards-Setting Likely To Run Longer Than Five Years
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
FDA's Rulemaking To-Do List Includes Dampening Pedigrees, Boosting Electronic Labeling
PDUFA Proposal Sheds Tier 3 Funding
NDA Data Standardization Efforts Emerging Along Public, Private Fronts
Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets
Next Up, Parkinson's: Coalition Against Major Diseases Moves To Link Neurodegenerative Ailments In Database





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts